foto1 foto2 foto3 foto4 foto5


Our news

  • 18/07/2019: Pharegis implemented optimized procedures for state registration of pharmaceuticals in Eurasian Economic Union.
  • 20/06/2019: Pharegis updated timelines and practical approaches for Russian and EEU GMP inspection applications and procedures.
  • 03/04/2019:  Renewed general monographs of Russian state pharmacopeia XIV ed. have been analyzed.

Contact us

Phone-Whatsapp-Telegram

+7 985 908 58 18

E-mail:      info@pharegis.com

pharegis.com | regdrug.com

enarzh-CNfrdeiwitjakoptruessv

Regulatory Events Russia

December 2021
S M T W T F S
28 29 30 1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31 1
January 2022
S M T W T F S
26 27 28 29 30 31 1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30 31 1 2 3 4 5

Russian Regulatory News

Drug registration in Ukraine, Kazakhstan, Belarus, Uzbekistan, Azerbaijan; regulatory consulting and clinical studies in CIS by CRO Pharegis

Registration of pharmaceuticals in EEU countries, Ukraine and Georgia

Regulatory systems for medical drugs and medical devices in Russia, Kazakhstan, Belarus, Armenia, Kyrgyzstan as members of Eurasian Economical Union (EEU) are expected to be changed with implementation of Mutual Recognition Procedure for EEU country members that will be actual already in 2016. 

Understanding your business and having experience in EEU (CIS) countries as well as Georgia and Ukraine, we can handle your registration activities to plan and minimize timeline for getting access to those countries’ promising markets.

Also we can handle communication activities regarding post-registration quality issues, Health authorities requests as well as pharmacovigilance/materiovigilance in those countries that you could focus on high priority projects.

SHARE THIS BY:

Regulatory news

Feed not found.

News and press releases

  • EMA and ECDC recommendations on heterologous vaccination courses against COVID-19, , 07/12/2021
  • ICMRA high-level meeting on global health emergencies and regulatory approaches, , 06/12/2021
  • EMA recommends approval for use of RoActemra in adults with severe COVID-19, CHMP, 06/12/2021
  • ICMRA and WHO map out flexibilities used by regulators to respond to the COVID-19 pandemic, , 03/12/2021
Feed not found.